search
Back to results

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension (CO in PAH)

Primary Purpose

Hypertension, Pulmonary

Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Carbon Monoxide
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension, Pulmonary focused on measuring Carbon Monoxide, Hypertension, Pulmonary

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • male and female ≥ 18 years old , with Pulmonary Arterial Hypertension

  • Right heart catheterization diagnosis of PAH:

    • Mean Pulmonary Artery Pressure (mPAP)> 25 mmHg at rest
    • Pulmonary Capillary Occlusion Pressure (PCOP) or Left Ventricular End Diastolic Pressure (LVEDP) < 15 mmHg
    • Pulmonary Vascular Resistance (PVR) > 3 mmHg/L/min
  • Must be Class 1.1, 1.2, or 1.3 PAH (see Appendix A)
  • Echocardiographic evidence of Right Ventricular Dysfunction

  • On standard and stable PAH therapy (no dose changes in the 4 weeks prior to starting the study medication) including:

    • A Prostacyclin (IV epoprostenol, IV or subcutaneous remodulin, inhaled iloprost or remodulin) unless willing or unable to tolerate therapy AND
    • Phosphodiesterase type 5 inhibitor OR
    • Endothelin Receptor Antagonist OR
    • Any combination of a-c
  • NYHA class III or IV despite 3 months of stable therapy as outlined above
  • 6 minute walk distance ≤ 380m
  • Negative serum pregnancy test
  • Female of childbearing age either surgically sterilized or using acceptable method of contraception. Acceptable methods of contraception include oral contraceptives, IUD, or other barrier methods of contraception.

Exclusion Criteria:

  • History of malignancy in 2 years prior to enrollment

  • Baseline cytopenia's:

    • White blood cell count ≤ 3,000 i. Absolute Neutrophil Count (ANC) less than 1500 cells/mm3
    • Hemoglobin ≤ 7
    • Platelet ≤ 100,000

  • Baseline Liver Disease:

    • ALT/AST, ALk phos > 2.5x ULN, INR > 1.5
    • Bilirubin > 1.5 x ULN
  • Coronary artery disease
  • Any cause of pulmonary hypertension other than class 1.1, 1.2, or 1.3 PAH.
  • Baseline Renal Disease: Cr ≥ 2
  • Active Smoker
  • Hypoxemia with SaO2 < 95% on oxygen 2 L/min
  • Baseline COHb > 2%
  • Pregnancy or lactation
  • Inability to attend scheduled clinic visits
  • Previous lung transplant
  • Naive to available standard PAH therapy
  • Pulmonary Capillary Occlusion Pressure (PCOP) or LEft Ventricular End Diastolic Pressure (LVEDP)< 15 mmHg
  • Concomitant enrollment in another investigational treatment protocol for PAH or taking any off label drug therapy for PAH
  • Recent enrollment in or plans to enroll in Pulmonary Rehabilitation during the study period
  • Any condition that in the opinion of the investigator would prevent completion of study procedures

Sites / Locations

  • University of Illinois at Chicago Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Carbon Monoxide

Arm Description

Inhaled Carbon Monoxide therapy administered over 16 weeks

Outcomes

Primary Outcome Measures

Evidence of a 20% decrease in pulmonary vascular resistance post-therapy when compared to pre-therapy value

Secondary Outcome Measures

Effect of 16-weeks CO inhalation on other pulmonary and systemic hemodynamic parameters
Effect of 16-weeks CO inhalation on functional capacity assessed by six-minute walk test
Effect of 16-weeks CO inhalation on Brain Natriuretic Peptide levels
Effect of 16-weeks CO inhalation on right ventricular echocardiographic parameters
Effect of 16-weeks CO inhalation on acute pulmonary vasoreactivity

Full Information

First Posted
January 27, 2012
Last Updated
June 8, 2017
Sponsor
University of Illinois at Chicago
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01523548
Brief Title
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Acronym
CO in PAH
Official Title
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of funding and subject acuity
Study Start Date
July 2012 (undefined)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to examine the potential of carbon monoxide (CO) to decrease elevated blood pressure in the pulmonary artery. This symptom is seen in patients with pulmonary arterial hypertension, a rare disease that causes fatigue, dizziness, and shortness of breath because the blood vessels that supply the lungs narrow, forcing the heart to work harder to push blood through. Previous studies in the laboratory have shown that carbon monoxide has promise in treating these symptoms. Subjects in this study are being asked to undergo a new type of treatment to improve pulmonary arterial hypertension by breathing CO gas. CO is a colorless, tasteless, odorless gas usually found in car exhaust or cigarette smoke. It is administered with a continuous flow of air. Subjects will undergo a screening process during which it will be determined if they are eligible for the study. After the screening process, if subjects meet eligibility criteria for the study, they will begin carbon monoxide treatment through a cushioned mask that is placed over the nose and mouth. This treatment will last for sixteen weeks.
Detailed Description
Pulmonary arterial hypertension (PAH) remains an uncommon debilitating and fatal disease, and is clinically marked by a progressive increase in pulmonary vascular resistance leading to right heart failure and ultimately death. Currently the treatment options available for those suffering from PAH target cellular dysfunction that leads to constriction of the vasculature. Although there is some evidence that available therapies have secondary effects on vascular remodeling there are currently no therapies that target abnormal cell proliferation in PAH. Carbon monoxide (CO) is a gaseous molecule with known toxicity and lethality to living organisms when exposed to high concentrations for sustained periods. However, CO has shown promise in preclinical models of pulmonary hypertension. Recent studies have shown that mammalian cells have the ability to generate endogenous CO primarily through the catalysis of heme by the heme oxygenase enzymatic system and there is ample evidence demonstrating that CO behaves as a signaling molecule in cellular and biological processes. Furthermore, CO has been demonstrated to exert key physiological and protective functions in various models of tissue inflammation and injury. This study will evaluate the safety and potential efficacy of inhaled CO in subjects with severe PAH. Over forty subjects with severe PAH despite best available therapy will be screened from the UIC pulmonary vascular disease clinic, of which twenty subjects will be recruited for participation in the trial. The trial will consist of an initial screening period to determine subjects' eligibility for the study. This will be based on a previous echocardiogram, a six minute walk test and right heart catheterization done as part of standard care for subjects with pulmonary arterial hypertension. Following the initial screening, the trial will last sixteen weeks, during which subjects will receive inhaled carbon monoxide up to three times weekly at the University of Illinois at Chicago.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Pulmonary
Keywords
Carbon Monoxide, Hypertension, Pulmonary

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Carbon Monoxide
Arm Type
Experimental
Arm Description
Inhaled Carbon Monoxide therapy administered over 16 weeks
Intervention Type
Drug
Intervention Name(s)
Carbon Monoxide
Intervention Description
150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
Primary Outcome Measure Information:
Title
Evidence of a 20% decrease in pulmonary vascular resistance post-therapy when compared to pre-therapy value
Time Frame
At baseline and after 16 weeks
Secondary Outcome Measure Information:
Title
Effect of 16-weeks CO inhalation on other pulmonary and systemic hemodynamic parameters
Time Frame
16 weeks
Title
Effect of 16-weeks CO inhalation on functional capacity assessed by six-minute walk test
Time Frame
16 weeks
Title
Effect of 16-weeks CO inhalation on Brain Natriuretic Peptide levels
Time Frame
16 weeks
Title
Effect of 16-weeks CO inhalation on right ventricular echocardiographic parameters
Time Frame
16 weeks
Title
Effect of 16-weeks CO inhalation on acute pulmonary vasoreactivity
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: male and female ≥ 18 years old , with Pulmonary Arterial Hypertension Right heart catheterization diagnosis of PAH: Mean Pulmonary Artery Pressure (mPAP)> 25 mmHg at rest Pulmonary Capillary Occlusion Pressure (PCOP) or Left Ventricular End Diastolic Pressure (LVEDP) < 15 mmHg Pulmonary Vascular Resistance (PVR) > 3 mmHg/L/min Must be Class 1.1, 1.2, or 1.3 PAH (see Appendix A) Echocardiographic evidence of Right Ventricular Dysfunction On standard and stable PAH therapy (no dose changes in the 4 weeks prior to starting the study medication) including: A Prostacyclin (IV epoprostenol, IV or subcutaneous remodulin, inhaled iloprost or remodulin) unless willing or unable to tolerate therapy AND Phosphodiesterase type 5 inhibitor OR Endothelin Receptor Antagonist OR Any combination of a-c NYHA class III or IV despite 3 months of stable therapy as outlined above 6 minute walk distance ≤ 380m Negative serum pregnancy test Female of childbearing age either surgically sterilized or using acceptable method of contraception. Acceptable methods of contraception include oral contraceptives, IUD, or other barrier methods of contraception. Exclusion Criteria: History of malignancy in 2 years prior to enrollment Baseline cytopenia's: White blood cell count ≤ 3,000 i. Absolute Neutrophil Count (ANC) less than 1500 cells/mm3 Hemoglobin ≤ 7 Platelet ≤ 100,000 Baseline Liver Disease: ALT/AST, ALk phos > 2.5x ULN, INR > 1.5 Bilirubin > 1.5 x ULN Coronary artery disease Any cause of pulmonary hypertension other than class 1.1, 1.2, or 1.3 PAH. Baseline Renal Disease: Cr ≥ 2 Active Smoker Hypoxemia with SaO2 < 95% on oxygen 2 L/min Baseline COHb > 2% Pregnancy or lactation Inability to attend scheduled clinic visits Previous lung transplant Naive to available standard PAH therapy Pulmonary Capillary Occlusion Pressure (PCOP) or LEft Ventricular End Diastolic Pressure (LVEDP)< 15 mmHg Concomitant enrollment in another investigational treatment protocol for PAH or taking any off label drug therapy for PAH Recent enrollment in or plans to enroll in Pulmonary Rehabilitation during the study period Any condition that in the opinion of the investigator would prevent completion of study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto F Machado, MD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois at Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension

We'll reach out to this number within 24 hrs